Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
- Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m.
- Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity.
UTRECHT, the Netherlands – 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering novel and highly differentiated therapies using its proprietary SureTACs™ precision membrane protein degradation platform, today announces the successful completion of the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m. This latest investment comes from new co-lead investor Biovance Capital and existing co-lead investor Kurma Partners.
